West Pharmaceutical
729 hedge funds and large institutions have $20.5B invested in West Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 294 increasing their positions, 271 reducing their positions, and 100 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8% more repeat investments, than reductions
Existing positions increased: 294 | Existing positions reduced: 271
0.79% more ownership
Funds ownership: 93.77% → 94.55% (+0.79%)
6% less funds holding
Funds holding: 776 → 729 (-47)
9% less capital invested
Capital invested by funds: $22.4B → $20.5B (-$1.93B)
39% less call options, than puts
Call options by funds: $92.1M | Put options by funds: $152M
40% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 100
Top Buyers
| 1 |
ProShare Advisors
Bethesda,
Maryland
|
+$197M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$176M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
+$162M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$122M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$115M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$132M |
| 2 |
Millennium Management
New York
|
-$121M |
| 3 |
BlackRock
New York
|
-$92.5M |
| 4 |
A
AustralianSuper
Melbourne,
Australia
|
-$90M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$86.6M |
WST Hedge Fund Activity: Q3 2024 in Review
729 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2024, worth a combined $20.5B — down 8.6% from $22.4B a quarter earlier.
Sellers outnumbered buyers: 100 funds closed out of WST and 60 opened new positions — a net loss of 40 holders — while 271 trimmed existing stakes and 294 added.
The largest buyer was ProShare Advisors, adding an estimated $197M. The largest seller was T. Rowe Price Associates, cutting an estimated $132M.
- 729 institutional investors held West Pharmaceutical (WST) as of Q3 2024, down from 776 in Q2 2024.
- Funds reported $20.5B of West Pharmaceutical stock for Q3 2024, down 8.6% quarter-over-quarter.
- 60 funds opened new West Pharmaceutical positions in Q3 2024 and 100 closed out, a net change of -40 holders.
- The largest West Pharmaceutical buyer in Q3 2024 was ProShare Advisors, an estimated $197M added.
- The largest West Pharmaceutical seller in Q3 2024 was T. Rowe Price Associates, an estimated $132M sold.
Based on aggregated 13F filings for Q3 2024.